ArticleBone & joint research2026
The evaluation of osteoconductive WE43 magnesium as a therapeutic approach for nonunion treatment : a mouse model.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Nonunion is a challenging condition marked by impaired bone healing and vascularization. While magnesium-based biomaterials show osteogenic and angiogenic potential, their role in nonunion remains controversial. Controlled modification of magnesium-based implants may enable regenerative osteogenesis. Methods: Here, WE43, a magnesium alloy, was investigated in a standardized femoral nonunion model in C57Bl/6 mice. Three groups were compared: WE43 alone, WE43 with cancellous bone (WE43+), and cancellous bone alone (control, CTR). Bone healing was assessed at eight and 12 weeks using micro-CT, histology, and immunohistochemistry. Key outcomes included defect bridging, bone volume, mineralization, trabecular metrics, osteoclast/osteoblast activity, and vascularization. Results: WE43+ significantly reduced defect size and improved bone formation and microvascular density, nearing control levels. In contrast, WE43 alone showed high osteoclast activity, poor mineralization, and fibrotic healing. Magnesium's regenerative performance depended strongly on degradation rate and osteoconductive support. Combining WE43 with cancellous bone improved osseointegration and angiogenesis. Conclusion: WE43 requires interaction with cancellous bone to support regeneration. Future studies should clarify which properties of cancellous bone enhance magnesium-based healing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.